Loading Events

Presenter: Barbara J Grabher BS, CNMT, RT(N), NCT, FSNMMI-TS
Manager, Application Specialist and Product Technology for Life Molecular Imaging

Barbara Grabher has been in the field of Nuclear Medicine for over 38 years, she earned her Associates Degree in Nuclear Medicine from Delaware Technical and Community College in 1983 and earned her bachelor’s degree in Organizational Management from Wilmington University in 2018. She is board-certified by the American Registry of Radiologic Technologists and the Nuclear Medicine Technology Certification Board in both Nuclear Medicine and as a Nuclear Cardiology Technologist. Ms. Grabher received her Nuclear Medicine fellowship status by the SNMMI Technologist section in June 2021 being one of only 109 Nuclear Medicine technologist in the country to receive this recognition. She’s given presentations at the local level as well as nationally, on topics related to both nuclear cardiology and neurology specializing in DaT imaging and movement disorders as well as amyloid imaging. She’s had 4 manuscripts published in the JNMT Technologist Journal on various topics. Ms. Grabher holds Six Sigma Greenbelt, LEAN and Blackbelt Certificates specializing in Healthcare. She is a member of the Society of Nuclear Medicine Technologist Section and has affiliations that include the Society of Nuclear Medicine, and the American Society of Radiologic Technologists. Ms. Grabher is currently a Clinical Applications Specialist for Life Molecular Imaging supporting the amyloid plaque imaging agent Neuraceq.

Date: January 11, 2023
Time: 3:30pm EST


Who should attend? PET Interpreters, Technologists, Referring Physicians, Marketers

In this webinar, Ms. Grabher will help you to:

  • understand the complex process companies go through when getting a radiopharmaceutical FDA approved
  • list the different phases of clinical trials from bench to approval when getting a tracer FDA approved
  • know the different types of FDA Applications and Approvals there are
  • realize the amount of time, money and resources companies use to hopefully get their tracer approved
  • understand the importance of clinical trials and the need for diverse patient population participation

Share This Story, Choose Your Platform!

Go to Top